ClinicalTrials.gg
CompletedNCT00082186Updated Feb 3, 2025

The Effect of Tracleer® on Male Fertility

A Phase 4 interventional study of bosentan in Hypertension, Pulmonary, sponsored by Actelion. Completed. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing bosentan in Hypertension, Pulmonary — none open to participants now, none under way, none of them phase 3. Bosentan · Hypertension, Pulmonary.

Enrollment
10th of 19
22 · median 22
Started
2003
the only one that year
Phase 4
6 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
9 of 19
Actelion

Among the 19 studies testing bosentan in Hypertension, Pulmonary, this one is the 10th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 4, and was the 1st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

None of the 19 studies testing bosentan in Hypertension, Pulmonary is open now. The open studies under Hypertension, Pulmonary, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing bosentan in Hypertension, Pulmonary as a file.
02

Study summary

The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PAH).

03

Conditions studied

  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients age 18-65 years.
  • Bosentan-naïve.
  • PPH, WHO functional class III/IV, in need of TRACLEER
  • Patients pulmonary arterial hypertension (PAH) secondary to congenital heart disease.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Female
  • Patients with PAH secondary to connective tissue vascular diseases or .
  • Patients who have undergone a vasectomy.
  • Patients with an average baseline sperm concentration \< 15 x 10[6]/mL, or any sample with a sperm concentration \<= 7.5 x 10[6]/mL.
  • Patients with an average baseline sperm motility \<20% or normal sperm morphology \<5%.
  • Body weight \< 50 kg.
  • Hypotension, defined as systolic blood pressure less than 85 mm Hg.
  • and/or ALT plasma levels greater than 3 times .
  • to bosentan or any of the components of the formulation.
  • Treatment with glyburide, cyclosporine A or tacrolimus at inclusion or planned during the study.
  • Treatment with hormone suppressive agents, including androgens, estrogens, anabolic steroids or within the past 6 months or planned during the study.
  • Current treatment less than 3 months prior to inclusion or planned treatment with prostacyclin or prostacyclin analogues (e.g., Flolanâ or Remodulin).
  • Patients who received an drug in the month preceding the study start or who are due to be treated with another investigational drug during the study period.
  • Known drug or alcohol dependence or any other factors that will interfere with conduct of the study.
  • Any illness other than PPH that will reduce to less than 6 months.
  • Active cancer.
  • Prior treatment with an anti-neoplastic agent or ionizing radiation.
  • Hot tub/Jacuzzi use.
  • Uncontrolled diseases including diabetes, liver or kidney disease.
  • Patients receiving spironolactone (aldactone) less than 3 months prior to inclusion or dose >25 mg/day at baseline or anytime during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    1

    Oral bosentan tablets

    Drug: bosentan

Interventions

  • Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.

    Also known as: Tracleer (R)

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a mean decrease in sperm concentration to 7.5 x 10[6]/mL or below, without a single sperm concentration ≥ 20 x 10[6]/mL, at 3 or 6 months. This proportion is considered of clinical relevance if greater than 30%.

    Time frame: From baseline to end of study.

Secondary outcomes

  1. Semen volume, sperm motility and sperm morphology change

    Time frame: From baseline to 3 & 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Feb 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2004
First posted
May 4, 2004
Start
Jul 2003
Primary completionActual
Feb 2007
CompletionActual
Nov 2007
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00082186
Lead sponsor
Actelion
First posted
May 4, 2004
Start date
Jul 2003
Primary completion
Feb 2007
Completion
Nov 2007
Last update
Feb 3, 2025

Study contacts

Andrea Lauer, Ph.D.
study director · Actelion Pharmaceuticals US, Inc.
Maurizio Rainisio, Ph.D.
study director · Actelion
Frederic Bodin, M.D.
study director · Actelion
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion